These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 7534665)
21. Expression of cytokeratins 13 and 16 in middle ear cholesteatoma. Sasaki H; Huang CC Otolaryngol Head Neck Surg; 1994 Mar; 110(3):310-7. PubMed ID: 7510866 [TBL] [Abstract][Full Text] [Related]
22. Morphologic and biologic changes of experimentally induced cholesteatoma in Mongolian gerbils with anticytokeratin and lectin study. Kim CS; Chung JW Am J Otol; 1999 Jan; 20(1):13-8. PubMed ID: 9918165 [TBL] [Abstract][Full Text] [Related]
23. The role of S100A1 in external auditory canal cholesteatoma. Naim R; Hormann K Oncol Rep; 2006 Oct; 16(4):671-5. PubMed ID: 16969478 [TBL] [Abstract][Full Text] [Related]
24. Expression of a cell-cycle-associated nuclear antigen (MIB 1) in cholesteatoma and auditory meatal skin. Sudhoff H; Bujía J; Fisseler-Eckhoff A; Holly A; Schulz-Flake C; Hildmann H Laryngoscope; 1995 Nov; 105(11):1227-31. PubMed ID: 7475881 [TBL] [Abstract][Full Text] [Related]
25. An immunocytochemical study of cytokeratin expression in human middle ear cholesteatoma. Chao WY; Huang CC Arch Otorhinolaryngol; 1989; 246(1):37-42. PubMed ID: 2472127 [TBL] [Abstract][Full Text] [Related]
26. Roles of cytokines and cell cycle regulating substances in proliferation of cholesteatoma epithelium. Tanaka Y; Kojima H; Miyazaki H; Koga T; Moriyama H Laryngoscope; 1999 Jul; 109(7 Pt 1):1102-7. PubMed ID: 10401849 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical demonstration of c-myc oncogene product in middle ear cholesteatoma. Holly A; Sittinger M; Bujia J Eur Arch Otorhinolaryngol; 1995; 252(6):366-9. PubMed ID: 8679157 [TBL] [Abstract][Full Text] [Related]
28. Role of Bcl-xL protein in differentiation and apoptosis of human middle ear cholesteatoma epithelium. Kojima H; Miyazaki H; Tanaka Y; Shiwa M; Koga T; Moriyama H Arch Otolaryngol Head Neck Surg; 1999 Jul; 125(7):738-42. PubMed ID: 10406309 [TBL] [Abstract][Full Text] [Related]
29. Bone resorption in chronic otitis media: the role of the osteoclast. Jung JY; Chole RA ORL J Otorhinolaryngol Relat Spec; 2002; 64(2):95-107. PubMed ID: 12021500 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical study of cytokeratin expression in normal and pathologic middle ear mucosa of the rat. Vennix PP; Kuijpers W; Tonnaer EL; Peters TA; Ramaekers FC Ann Otol Rhinol Laryngol; 1990 Dec; 99(12):998-1004. PubMed ID: 1700893 [TBL] [Abstract][Full Text] [Related]
31. [The expression and significance of human beta-defensin 2 in middle ear cholesteatoma epithelium]. Ren X; Cui P; Chen W; Xu M Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Apr; 19(7):313-4. PubMed ID: 16001900 [TBL] [Abstract][Full Text] [Related]
32. The nature of the epithelium in acquired cholesteatoma. Lee RJ; Mackenzie IC; Hall BK; Gantz BJ Clin Otolaryngol Allied Sci; 1991 Apr; 16(2):168-73. PubMed ID: 1712679 [TBL] [Abstract][Full Text] [Related]
33. Activation of NLRP3 inflammasome in human middle ear cholesteatoma and chronic otitis media. Kariya S; Okano M; Zhao P; Kataoka Y; Yoshinobu J; Maeda Y; Ishihara H; Higaki T; Nishizaki K Acta Otolaryngol; 2016; 136(2):136-40. PubMed ID: 26457439 [TBL] [Abstract][Full Text] [Related]
34. HB-EGF expression as a potential biomarker of acquired middle ear cholesteatoma. Xie S; Wang X; Ren H; Liu X; Ren J; Liu W Acta Otolaryngol; 2017 Aug; 137(8):797-802. PubMed ID: 28498080 [TBL] [Abstract][Full Text] [Related]
35. Nucleoplasm staining patterns and cell cycle-associated expression of Ki-67 in middle ear cholesteatoma. Raynov AM; Moon SK; Choung YH; Hong SP; Park K Am J Otolaryngol; 2005; 26(5):296-301. PubMed ID: 16137526 [TBL] [Abstract][Full Text] [Related]
36. Involvement of interleukin-1 in middle ear cholesteatoma. Shiwa M; Kojima H; Kamide Y; Moriyama H Am J Otolaryngol; 1995; 16(5):319-24. PubMed ID: 7503375 [TBL] [Abstract][Full Text] [Related]
37. [The significance of keratinocyte in hyperproliferation of middle ear cholesteatoma]. Zhu Z; Hong Y; Wang Y; He G; Ye S Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jan; 30(2):139-43. PubMed ID: 27192911 [TBL] [Abstract][Full Text] [Related]
38. [The expression of Ras protein in human middle ear cholesteatoma]. Xu Y; Jin K; Dong W Zhonghua Er Bi Yan Hou Ke Za Zhi; 1999 Apr; 34(2):74-6. PubMed ID: 12764851 [TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical study on proliferative activity of experimental cholesteatoma. Park K; Park HJ; Chun YM Eur Arch Otorhinolaryngol; 2001 Mar; 258(3):101-5. PubMed ID: 11374247 [TBL] [Abstract][Full Text] [Related]
40. Osteoclastic activity in chronic otitis media with cholesteatoma-related bone destruction. Özgür A; Yemiş T; Başbulut E; Turgut NF; Özdemir D; Akgül G; Mehel DM; Çelebi M J Laryngol Otol; 2021 Oct; 135(10):879-882. PubMed ID: 34348812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]